Search

Your search keyword '"Ruttens, D."' showing total 189 results
Start Over Author "Ruttens, D."
189 results on '"Ruttens, D."'

3. Flemish network on rare connective tissue diseases (CTD):patient pathways in systemic sclerosis. First steps taken

Author

Piette, Y., Van den Bossche, F., Aerts, J., Aerts, N., Ajeganova, S., Badot, V., Berghen, N., Blockmans, D., Brusselle, G., Caeyers, N., De Decker, M., De Haes, P., De Cock, C., De Keyser, F., De Langhe, E., Delcroix, M., De Nutte, H., De Pauw, M., Depicker, A., De Sutter, A., De Sutter, J., Du Four, T., Frank, C., Goubau, J., Guiot, J., Gutermuth, J., Heeman, L., Houssiau, F., Hennes, I., Lenaerts, J., Lintermans, A., Loeys, B., Luyten, H., Maeyaert, B., Malfait, F., Moeyersoons, A., Mostmans, Y., Nijs, J., Poppe, B., Polfliet, K., Ruttens, D., Sabato, V., Schoeters, E., Slabbynck, H., Stuer, A., Tamirou, F., Thevissen, Kristof, Van Kersschaever, G., Vanneuville, B., Van Offel, J., Vanthuyne, M., Van Wabeke, J., Verbist, C., Vos, I., Westhovens, R., Wuyts, W., Yserbyt, J., Smith, V., Piette, Y., Van den Bossche, F., Aerts, J., Aerts, N., Ajeganova, S., Badot, V., Berghen, N., Blockmans, D., Brusselle, G., Caeyers, N., De Decker, M., De Haes, P., De Cock, C., De Keyser, F., De Langhe, E., Delcroix, M., De Nutte, H., De Pauw, M., Depicker, A., De Sutter, A., De Sutter, J., Du Four, T., Frank, C., Goubau, J., Guiot, J., Gutermuth, J., Heeman, L., Houssiau, F., Hennes, I., Lenaerts, J., Lintermans, A., Loeys, B., Luyten, H., Maeyaert, B., Malfait, F., Moeyersoons, A., Mostmans, Y., Nijs, J., Poppe, B., Polfliet, K., Ruttens, D., Sabato, V., Schoeters, E., Slabbynck, H., Stuer, A., Tamirou, F., Thevissen, Kristof, Van Kersschaever, G., Vanneuville, B., Van Offel, J., Vanthuyne, M., Van Wabeke, J., Verbist, C., Vos, I., Westhovens, R., Wuyts, W., Yserbyt, J., and Smith, V.

Abstract

Despite the low prevalence of each rare disease, the total burden is high. Patients with rare diseases encounter numerous barriers, including delayed diagnosis and limited access to high-quality treatments. In order to tackle these challenges, the European Commission launched the European Reference Networks (ERNs), cross-border networks of healthcare providers and patients representatives. In parallel, the aims and structure of these ERNs were translated at the federal and regional levels, resulting in the creation of the Flemish Network of Rare Diseases. In line with the mission of the ERNs and to ensure equal access to care, we describe as first patient pathways for systemic sclerosis (SSc), as a pilot model for other rare connective and musculoskeletal diseases. Consensus was reached on following key messages: 1. Patients with SSc should have multidisciplinary clinical and investigational evaluations in a tertiary reference expert centre at baseline, and subsequently every three to 5 years. Intermediately, a yearly clinical evaluation should be provided in the reference centre, whilst SSc technical evaluations are permissionably executed in a centre that follows SSc-specific clinical practice guidelines. In between, monitoring can take place in secondary care units, under the condition that qualitative examinations and care including interactive multidisciplinary consultations can be provided. 2. Patients with early diffuse cutaneous SSc, (progressive) interstitial lung disease and/or pulmonary arterial hypertension should undergo regular evaluations in specialised tertiary care reference institutions. 3. Monitoring of patients with progressive interstitial lung disease and/or pulmonary (arterial) hypertension will be done in agreement with experts of ERN LUNG.

Published
2024

4. Flemish network on rare connective tissue diseases (CTD): patient pathways in systemic sclerosis. First steps taken

Author

Piette, Y., primary, Van den Bossche, F., additional, Aerts, J., additional, Aerts, N., additional, Ajeganova, S., additional, Badot, V., additional, Berghen, N., additional, Blockmans, D., additional, Brusselle, G., additional, Caeyers, N., additional, De Decker, M., additional, De Haes, P., additional, De Cock, C., additional, De Keyser, F., additional, De Langhe, E., additional, Delcroix, M., additional, De Nutte, H., additional, De Pauw, M., additional, Depicker, A., additional, De Sutter, A., additional, De Sutter, J., additional, Du Four, T., additional, Frank, C., additional, Goubau, J., additional, Guiot, J., additional, Gutermuth, J., additional, Heeman, L., additional, Houssiau, F., additional, Hennes, I., additional, Lenaerts, J., additional, Lintermans, A., additional, Loeys, B., additional, Luyten, H., additional, Maeyaert, B., additional, Malfait, F., additional, Moeyersoons, A., additional, Mostmans, Y., additional, Nijs, J., additional, Poppe, B., additional, Polfliet, K., additional, Ruttens, D., additional, Sabato, V., additional, Schoeters, E., additional, Slabbynck, H., additional, Stuer, A., additional, Tamirou, F., additional, Thevissen, Kristof, additional, Van Kersschaever, G., additional, Vanneuville, B., additional, Van Offel, J., additional, Vanthuyne, M., additional, Van Wabeke, J., additional, Verbist, C., additional, Vos, I., additional, Westhovens, R., additional, Wuyts, W., additional, Yserbyt, J., additional, and Smith, V., additional

Published
2023
Full Text
View/download PDF

5. A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study

Author

Vanassche, T., Engelen, M. M., Van Thillo, Q., Wauters, J., Gunst, J., Wouters, C., Vandenbriele, C., Rex, S., Liesenborghs, L., Wilmer, A., Meersseman, P., Van den Berghe, G., Dauwe, D., Verbeke, G., Thomeer, M., Fivez, T., Mesotten, D., Ruttens, D., Heytens, L., Dapper, I., Tuyls, S., De Tavernier, B., and Verhamme, P.

Published
2020
Full Text
View/download PDF

8. Flemish network on rare connective tissue diseases (CTD): patient pathways in systemic sclerosis. First steps taken

Author

Piette, Y., Van den Bossche, F., Aerts, J., Aerts, N., Ajeganova, S., Badot, V., Berghen, N., Blockmans, D., Brusselle, G., Caeyers, N., De Decker, M., De Haes, P., De Cock, C., De Keyser, F., De Langhe, E., Delcroix, M., De Nutte, H., De Pauw, M., Depicker, A., De Sutter, A., De Sutter, J., Du Four, T., Frank, C., Goubau, J., Guiot, J., Gutermuth, J., Heeman, L., Houssiau, F., Hennes, I., Lenaerts, J., Lintermans, A., Loeys, B., Luyten, H., Maeyaert, B., Malfait, F., Moeyersoons, A., Mostmans, Y., Nijs, J., Poppe, B., Polfliet, K., Ruttens, D., Sabato, V., Schoeters, E., Slabbynck, H., Stuer, A., Tamirou, F., Thevissen, Kristof, Van Kersschaever, G., Vanneuville, B., Van Offel, J., Vanthuyne, M., Van Wabeke, J., Verbist, C., Vos, I., Westhovens, R., Wuyts, W., Yserbyt, J., and Smith, V.

Abstract

ABSTRACTDespite the low prevalence of each rare disease, the total burden is high. Patients with rare diseases encounter numerous barriers, including delayed diagnosis and limited access to high-quality treatments. In order to tackle these challenges, the European Commission launched the European Reference Networks (ERNs), cross-border networks of healthcare providers and patients representatives. In parallel, the aims and structure of these ERNs were translated at the federal and regional levels, resulting in the creation of the Flemish Network of Rare Diseases. In line with the mission of the ERNs and to ensure equal access to care, we describe as first patient pathways for systemic sclerosis (SSc), as a pilot model for other rare connective and musculoskeletal diseases. Consensus was reached on following key messages: 1. Patients with SSc should have multidisciplinary clinical and investigational evaluations in a tertiary reference expert centre at baseline, and subsequently every three to 5 years. Intermediately, a yearly clinical evaluation should be provided in the reference centre, whilst SSc technical evaluations are permissionably executed in a centre that follows SSc-specific clinical practice guidelines. In between, monitoring can take place in secondary care units, under the condition that qualitative examinations and care including interactive multidisciplinary consultations can be provided. 2. Patients with early diffuse cutaneous SSc, (progressive) interstitial lung disease and/or pulmonary arterial hypertension should undergo regular evaluations in specialised tertiary care reference institutions. 3. Monitoring of patients with progressive interstitial lung disease and/or pulmonary (arterial) hypertension will be done in agreement with experts of ERN LUNG.

Published
2024
Full Text
View/download PDF

27. Differential Airway Involvement in Restrictive Phenotypes of Chronic Lung Allograft Dysfunction

Author

Verleden, S.E., primary, Vos, R., additional, Ruttens, D., additional, Vandermeulen, E., additional, Bellon, H., additional, Mcdonough, J., additional, Verbeken, E., additional, Verschakelen, J., additional, Van Raemdonck, D.E., additional, Rondelet, B., additional, Knoop, C., additional, Hogg, J., additional, Verleden, G., additional, and Vanaudenaerde, B.M., additional

Published
2015
Full Text
View/download PDF

32. Role of genetics in lung transplant complications

Author

Ruttens, D., primary, Vandermeulen, E., additional, Verleden, S. E., additional, Bellon, H., additional, Vos, R., additional, Van Raemdonck, D. E., additional, Dupont, L. J., additional, Vanaudenaerde, B. M., additional, and Verleden, G. M., additional

Published
2015
Full Text
View/download PDF

37. The Impact of Air Pollution on Outcome After Lung Transplantation in Europe

Author

Verleden, S.E., primary, Ruttens, D., additional, Bijnens, E., additional, Winckelmans, E., additional, Meloni, F., additional, Morosini, M., additional, Gottlieb, J., additional, Warnecke, G., additional, Verschuuren, E., additional, Van Der Bij, W., additional, Weinreich, G., additional, Kamler, M., additional, Sommerwerck, U., additional, Hoffmann, B., additional, Roman, A., additional, Gomez Olles, S., additional, Benden, C., additional, Rechsteiner, T., additional, Luijck, B., additional, Oudijk, E., additional, Van Kessel, D., additional, Kwakkel-Van Erp, J., additional, Iversen, M., additional, Schultz, H., additional, Jaksch, P., additional, Klepetko, W., additional, Lordan, J., additional, Corris, P., additional, Fisher, A., additional, Holm, A., additional, Vandermeulen, E., additional, Vos, R., additional, Kneidinger, N., additional, Neurohr, C., additional, Beelen, R., additional, Vienneau, D., additional, Hoek, G., additional, De Hoogh, K., additional, Nemery, B., additional, Verleden, G.M., additional, Nawrot, T.S., additional, and Vanaudenaerde, B., additional

Published
2014
Full Text
View/download PDF

38. Airway Alterations in Chronic Lung Allograft Dysfunction

Author

Verleden, S.E., primary, Vasilescu, D., additional, Willems, S., additional, Ruttens, D., additional, Vos, R., additional, Vandermeulen, E., additional, Mcdonough, J., additional, Verbeken, E., additional, Verschakelen, J., additional, Van Raemdonck, D., additional, Rondelet, B., additional, Knoop, C., additional, Decramer, M., additional, Cooper, J., additional, Hogg, J., additional, Hostens, J., additional, Verleden, G., additional, and Vanaudenaerde, B., additional

Published
2014
Full Text
View/download PDF

41. Immediate Post-Operative Bronchoalveolar IL-6 and IL-8 Cytokine Levels Are Associated with Short-Term Patient Outcome and Long-Term Allograft Outcome after Lung Transplantation

Author

Vos, R., primary, Ruttens, D., additional, Verleden, S., additional, Vaneylen, A., additional, Vandermeulen, E., additional, Somers, J., additional, Van Raemdonck, D.E., additional, Yserbyt, J., additional, Dupont, L.J., additional, Vanaudenaerde, B.M., additional, and Verleden, G.M., additional

Published
2013
Full Text
View/download PDF

43. Outcome after Lung Transplantation Is Comparable between DCD and DBD

Author

Van Raemdonck, D., primary, Vanaudenaerde, B., additional, Verleden, S., additional, Ruttens, D., additional, Vos, R., additional, Dupont, L., additional, Delcroix, M., additional, Wuyts, W., additional, Yserbyt, J., additional, Neyrinck, A., additional, Coosemans, W., additional, Decaluwé, H., additional, De Leyn, P., additional, Nafteux, P., additional, Van Veer, H., additional, and Verleden, G.M., additional

Published
2013
Full Text
View/download PDF

46. New Insights in Bronchiolitis Obliterans Syndrome after Lung Transplantation Using (micro-)CT

Author

Verleden, S.E., primary, Vasilescu, D., additional, Willems, S., additional, Ruttens, D., additional, Vandermeulen, E., additional, Vaneylen, A., additional, Van Raemdonck, D.E., additional, Vos, R., additional, Mcdonough, J.E., additional, Verbeken, E.K., additional, Verschaekelen, J., additional, Rondelet, B., additional, Knoop, C., additional, Cooper, J., additional, Decraemer, M.L., additional, Hogg, J.C., additional, Verleden, G.M., additional, and Vanaudenaerde, B.M., additional

Published
2013
Full Text
View/download PDF

48. Functional Association between a Genetic Variant in the IL-17 Receptor Gene and Chronic Rejection after Lung Transplantation

Author

Ruttens, D., primary, Wauters, E., additional, Kicinski, M., additional, Verleden, S.E., additional, Vaneylen, A., additional, Vandermeulen, E., additional, Vos, R., additional, Van Raemdonck, D.E., additional, Nawrot, T.S., additional, Lambrechts, D., additional, Verleden, G.M., additional, and Vanaudenaerde, B., additional

Published
2013
Full Text
View/download PDF

50. 88 Acute Rejection after Lung Transplantation Is Associated with Daily Changes in Air Pollution

Author

Verleden, S.E., primary, Scheers, H., additional, Nawrot, T.S., additional, Fierens, F., additional, Vos, R., additional, Geenens, R., additional, Yserbyt, J., additional, Wauters, S., additional, Somers, J., additional, Ruttens, D., additional, Van Eylen, A., additional, Verbeken, E.K., additional, Nemery, B., additional, Van Raemdonck, D.E., additional, Verleden, G.M., additional, and Vanaudenaerde, B.M., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results